Welcome to our dedicated page for Monopar Therapeutics SEC filings (Ticker: MNPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Monopar Therapeutics Inc. filings document a clinical-stage biopharmaceutical issuer focused on ALXN1840 for Wilson disease and MNPR-101 radiopharmaceutical programs for uPAR-expressing cancers. Its 8-K reports furnish financial results, business updates, Regulation FD clinical presentations, conference materials and executive leadership changes, including ALXN1840 Phase 2 and Phase 3 analyses and MNPR-101 program regulatory updates.
Proxy and material-event filings cover shareholder voting matters, board governance, executive compensation, pay-versus-performance tables, capital-structure disclosures and material agreements. The filing record also provides formal context for reported operating results, financing activity and disclosures tied to investigational drug development and Nasdaq-listed common stock.
Monopar Therapeutics Inc. (MNPR) filed an 8-K to disclose the results of its 17 June 2025 Annual Meeting of Stockholders. Of the 6,115,214 shares entitled to vote, 82.6% (5,048,394) were represented in person or by proxy.
- Director elections: All six nominees—including CEO Chandler D. Robinson and Chair Christopher M. Starr—were elected. Support ranged from 78.7% to 99.9% of votes cast, with 655,826 broker non-votes recorded for each nominee.
- Say-on-pay: Executive compensation was approved with 4,382,795 votes for (99.8%), 2,933 against, and 6,840 abstentions.
- Say-on-pay frequency: Shareholders selected an annual advisory vote, receiving 4,383,765 votes, dwarfing biennial (1,247) and triennial (1,212) options.
- Auditor ratification: BPM LLP was ratified as independent accountant for FY-2025 with 5,044,817 votes for (99.9%).
No other matters were submitted. The outcome signals continued shareholder support for current governance, compensation practices, and audit oversight. No immediate financial impact or strategic change was disclosed.